Immune tolerance is essential for safeguarding the body’s own tissues from immune system attacks. During pregnancy, the maternal immune system tolerates the semi-allogeneic fetus through mechanisms such as placental programmed cell death 1 (PD-1)-ligand 1 (PD-L1) expression, regulatory T cells (Tregs), cytokine modulation, and hormonal changes. Placental PD-L1 is particularly important in suppressing maternal immune responses and preventing fetal rejection. Following delivery, the loss of the PD-L1-rich placenta can destabilize immune tolerance, potentially leading to postpartum autoimmune diseases such as fulminant type 1 diabetes, characterized by rapid insulin depletion and severe hyperglycemia. Similarly, immune checkpoint inhibitors (ICIs), widely used in cancer immunotherapy, block immune checkpoints like PD-1 and PD-L1 to enhance antitumor immunity by disrupting immunotolerance to tumors. However, this mechanism can sometimes result in immune-related adverse events (irAEs), including fulminant type 1 diabetes. Given the critical role of HLA haplotypes and environmental factors in the development of autoimmune conditions, identifying shared factors among postpartum individuals and patients undergoing ICI therapy who experience immune system abnormalities could provide valuable insights. Such understanding may improve strategies for managing autoimmune diseases associated with both postpartum immune changes and ICI treatments.

SET domain bifurcated 1 (SETDB1), a histone H3K9-specific methyltransferase, is crucial for heterochromatin formation and intestinal homeostasis, but its role in intestinal ischemia-reperfusion injury (IRI) remains unclear. This study investigated changes in SETDB1-mediated nuclear chromatin regulation in intestinal epithelial cells (IECs) using an IRI mouse model. Jejunal samples were collected after 75 min of ischemia followed by 24 hr of reperfusion. Sinefungin was administered as a histone methyltransferase inhibitor. Morphologic changes were evaluated using hematoxylin-eosin staining and electron microscopy, and cell-adhesion molecule expression, including ZO-1, E-cadherin, integrin-β4, and laminin, was evaluated using immunohistochemistry. Super-resolution microscopy analyzed intranuclear SETDB1 localization and heterochromatin formation in IECs. IRI-affected jejunum exhibited massive IEC detachment, dilated intercellular spaces, basement membrane damage, and decreased expression of E-cadherin and integrin-β4. Sinefungin prevented these changes, however. The proportion of IECs expressing nuclear SETDB1 throughout the euchromatin was significantly higher in IRI-affected jejunum (77.8%) than sham-treated (3.0%) or sinefungin-treated, IRI-affected jejunum (2.7%). The proportion of IECs with decreased heterochromatin was significantly higher in sinefungin-treated, IRI-affected jejunum (84.3%) than untreated IRI-affected jejunum (15.6%). These findings suggest that SETDB1-mediated chromatin regulation is pivotal in intestinal IRI and represents a potential therapeutic target.

Spinal cord injury (SCI) is incurable and often leads to permanent motor dysfunction, paralysis, and sensory impairment. We previously developed a method to directly reprogram human fibroblasts into neuron-like cells using only chemical compounds. In a rat model of SCI, we transplanted chemically reprogrammed cells, termed immature chemical-induced neuron-like (CiN) cells, derived using the developed method with slight modifications and found that the immature CiN cells exhibited therapeutic efficacy in SCI. As primate models more closely mimic humans than rat models, primate experiments are required to more accurately assess the safety and efficacy of immature CiN cells before their use in humans. Therefore, in this study, we aimed to determine the therapeutic efficacy of immature CiN cell transplantation in a marmoset SCI model. Immature CiN cells were transplanted into a subacute marmoset model of SCI on Day 9 after contusion injury, and the therapeutic efficacy was assessed. Motor recovery after SCI was assessed based on spontaneous motor activity and the original open-field rating scale over six weeks, after which the spinal cord at the injury site was subjected to histopathological and MRI analyses. Animals transplanted with immature CiN cells exhibited significantly enhanced motor recovery compared to control animals, consistent with improved nerve recovery or preservation. Our findings suggest that immature CiN cells can effectively treat SCI in primates.